2016 Annual Meeting Presentations

Annual Meeting

>> 2016 Agenda

Presentations are provided in PDF with author's permission. Use the links below to find the session you're looking for. Sessions and presentations will be added as permissions are provided. For presentations that are not provided contact IMPAACT Operations for contact information.

Joint Plenary

IMPAACT Plenary 1

Study Coordinators Meeting

IMPAACT Plenary 2

TB Scientific Committee

Complications and Co-Morbidities Scientific Committee

Treatment Scientific Committee

Cure Scientific Committee

Prevention Scentific Committee

Adherence Working Group

IMPAACT Community Advisory Board

Joint Plenary

Wednesday, June 15, 2016


NIAID: State of the Institute and Priorities in HIV/AIDS Research


Anthony Fauci


IMPAACT State of the Network


Sharon Nachman


Optimizing Treatment for Children and Adolescents: The Power of Now


Martina Penazzato

 

IMPAACT Plenary (1)

Wednesday, June 15, 2016


Update on IMPAACT Research Agenda: Scientific Committee’s Priorities & Accomplishments


Sharon Nachman


Targeted and Long-acting cART—A Systems Approach to Overcome Drug Insufficiency in Lymphatic Tissues and Cells (Contact IMPAACT Operations Center)


Rodney JY Ho


A5300/I2003/PHOENIx Preparatory Study of MDR TB Cases and Their Household Contacts: Operational Feasibility to Inform PHOENIx Trial (Contact IMPAACT Operations Center)


Amita Gupta

 

Study Coordinators Meeting

Wednesday, June 15, 2016


MediData Rave Q&A


Mary Wojcik-Cross and Marlene Cooper

Round-Table Discussions

This session included two, sequential, 30-min roundtable discussions

Clinical Quality Management Plan (CQMP)


Bariatu Smith


Intensive PK


Emily Barr and Deb McLaud


Adherence Strategies


Nishi Suryavanshi and Nasreen Abrahams


Study Activation


Katie McCarthy


Protocol Template


Anne Coletti


Enrolling into P1115, P1112, and/or P1110


Joan Coetzee


Transitioning participants from study to non-study care


Sukunena Maturure and Mercy Mutambanengwe

IMPAACT Site Overviews


Emory Univ SOM (5030)


Bridget Wynn and Alexis Daugherty


Baylor-Uganda (31798)


Violet Korutaro


Desmond Tutu TB Centre (31790)


Frieda Verheye-Dua


Kenya Medical Research Institute (5121)


Samwel Chirchir

 

IMPAACT Plenary (2)

Thursday, June 16, 2016


Mothers, Milk and Microbes: How To Make Healthy Babies (Contact IMPAACT Operations Center)


Grace Aldrovandi


Statistical Issues in IMPAACT Studies


David Shapiro


Medidata Rave and CDISC: Implementation Update


Marlene Cooper

 

TB Scientific Committee

Monday, June 13, 2016


2016 Updates from the Tuberculosis Scientific Committee and PHOENIx, a Trial of MDR-TB Prevention in Households


Anneke Hesseling and Amita Gupta


TB Trials in Adults and Opportunities for Children and Pregnant Women for MDR-TB, DS-TB


Kelly Dooley


Emerging Data on Key Second Line TB drugs in Children: Levofloxacin and Amikacin (Contact IMPAACT Operations Center)


Tony Garcia-Prats


Designing a MDR-TB Injectable Sparing Regimen in Children: Research Priorities, Design Considerations and Discussion


Anneke Hesseling and Simon Schaaf


Application of Pharmacometrics to TB PK Studies in Children and Pregnant Women – Case Based Experiences


Rada Savic


TB Biomarkers and Applications for TB Prevention Trials (Contact IMPAACT Operations Center)


Thomas Scriba


Utility of IGRAs in HIV-exposed and Infected Children in the IMPAACT P1041 TB Prevention Trial (Contact IMPAACT Operations Center)


Lisa Cranmer

 

Complications and Co-Morbidities Scientific Committee

Monday, June 13, 2016

Neurodevelopment and Mental Health


Biomarkers and HAND: What can ICAM-5 tell us about the immune system? (Contact IMPAACT Operations Center)


Harris A. Gelbard


Update on IMPAACT P1104s


Michael J. Boivin


Update on Study Development of Inflammation and Neurodevelopment


Adriana Weinberg


Update on IMPAACT P1080 (Contact IMPAACT Operations Center)


Brookie Best


Update on IMPAACT 2002


Larry Brown


CAP 519: Evaluating a Mental Health Intervention to Improve Mental Health Outcomes in HIV-Infected Adolescents in Low Resource Settings


Geri Donenberg

Metabolic and Infectious Complications


Update on IMPAACT P1063


Ann Melvin


Update on IMPAACT P1076 (Contact IMPAACT Operations Center)


George Siberry


Update on IMPAACT 2011, 2012, 2013 (Contact IMPAACT Operations Center)


Betsy McFarland

 

Treatment Scientific Committee

Tuesday, June 14, 2016


Welcome/Overview of Treatment Scientific Agenda


Elaine Abrams and Ted Ruel

Early Infant Treatment


The Present and Future of Early Infant Treatment (Contact IMPAACT Operations Center)


Martina Penazzato

Nevirapine


Pharmacokinetics of Nevirapine for Prophylaxis in Premature/Low Birth Weight Infants in IMPAACT P1106 (Contact IMPAACT Operations Center)


Adrie Bekker


Modelled Treatment Dosing and Preliminary Pharmacokinetic and Safety Data from IMPAACT P1115 and BHP-074


Brookie Best


Nevirapine Dosing in High Risk Thai Infants (PHPT-5) (Contact IMPAACT Operations Center)


Tim R. Cressey

Raltegravir


Neonatal Population Pharmacokinetic Data from IMPAACT P1097, P1110, and P1066 (Contact IMPAACT Operations Center)


Diana Clarke


Pharmacokinetics and Safety Data from IMPAACT P1110 Cohort 2, Infants Receiving Daily Dosing (Contact IMPAACT Operations Center)


Diana Clarke

Dolutegravir


Pregnancy/Washout Pharmacokinetic Data and Congenital Anomalies from IMPAACT P1026s (Contact IMPAACT Operations Center)


Mark Mirochnick


Dosing in IMPAACT P1093 Cohort III, Granules Among Children 2 to 6 years of age (Contact IMPAACT Operations Center)


Ted Ruel

Upcoming IMPAACT Treatment Studies


IMPAACT 2006


Paul Palumbo


New Lopinavir/Ritonavir Formulation (Contact IMPAACT Operations Center)


Marc Lallemant


IMPAACT 2010


Judy Currier


Discussion, Conclusions, and Next Steps


Elaine Abrams and Ted Ruel

 

Cure Scientific Committee

Tuesday, June 14, 2016


Welcome and Overview of Cure Committee Activities (Contact IMPAACT Operations Center)


Deborah Persaud


IMPAACT P1115 Update (Contact IMPAACT Operations Center)


Ellen Chadwick


Enlisting Effector Cells to Clear HIV Infection


David Margolis


Repeated TLR7 Agonist Treatment of SIV-Infected Monkeys on ART Can Induce Viral Remission (Contact IMPAACT Operations Center)


James Whitney and Romas Geleziunas


Virus-Specific T Cells after Transplant: Broadening Applicability to HIV


Michael Keller

 

Prevention Scentific Committee

Tuesday, June 14, 2016

Primary Prevention in Adolescents and Youth – ARV Strategies


PrEP Drug Pipeline – What Lies Beyond Truvada®? (Contact IMPAACT Operations Center)


Raphy Landovitz


Study update: IMPAACT 2009 - Pharmacokinetics, Adherence, Feasibility and Safety of Daily Tenofovir Oral PrEP During Pregnancy and Breastfeeding


Ben Chi

Immune Strategies for HIV Prevention


Getting to Zero - HIV Vaccines to Eliminate the Pediatric HIV-1 Epidemic


Sallie Permar


Study update: IMPAACT 2004 – Phase I Study to Determine Safety and Immunogenicity of Clade C ALVAC-HIV (vCP2438) in HIV-Exposed Infants


Sallie Permar


Study update: IMPAACT P1112 - Phase 1 Study to Determine Safety and PK Parameters of VRC01 in HIV-Exposed Infants (Contact IMPAACT Operations Center)


Coleen Cunningham


CAP 523: Alternative Vaccine Candidate CH505 (Contact IMPAACT Operations Center)


Giny Fouda

Prevention of Vertical Transmission of HIV


Study update: IMPAACT 1077 (PROMISE)


Mary Glenn Fowler


Next Steps for PMTCT


Maxie Owor

 

Adherence Working Group

Tuesday, June 14, 2016


Welcome and Year in Review (Contact IMPAACT Operations Center)


K. Rivet Amico and Sybil Hosek


A5300B/IMPAACT 2003B – PHOENIx MDR TB


Amita Gupta


IMPAACT 2010


Lynda Stranix-Chibanda


IMPAACT 2009


Benjamin Chi


CAP 515: Acceptability of Long Acting Injectable Antiretrovirals for Adolescents and Children (Contact IMPAACT Operations Center)


Elizabeth Lowenthal


PROMISE 1077HS


Judy Currier


Goals for 2016-2017 (Contact IMPAACT Operations Center)


K. Rivet Amico

 

IMPAACT Community Advisory Board

See Presentations

 

 


Funded by the National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the National Institute of Mental Health of the US National Institutes of Health, US Department of Health and Human Services.